Adcytherix

Executive Summary

Adcytherix is a privately held, preclinical-stage biotechnology company headquartered in San Diego, CA, dedicated to developing innovative antibody-based therapeutics for oncology. Founded in 2023, the company has raised $105 million to advance its pipeline of novel monoclonal and engineered antibodies that selectively modulate targets within the tumor microenvironment or on cancer cells. Adcytherix's approach aims to enhance anti-tumor immunity or directly inhibit tumor growth, positioning it to address significant unmet needs in immuno-oncology. With a lean team of 1-50 employees, the company is leveraging its antibody engineering expertise to progress multiple preclinical programs toward the clinic. The substantial capital raise at such an early stage underscores investor confidence in its platform and scientific strategy.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead Antibody Candidate40% success
• Q3 2026Presentation of Preclinical Efficacy Data at Major Conference60% success
• Q4 2026Series B or Partnership Announcement50% success